Oral Fludarabine Gives Antisoma Breathing Room
This article was originally published in The Pink Sheet Daily
Executive Summary
Antisoma’s deal with Sanofi-Aventis provides two years of cash, allowing the biotech to focus on its pipeline.
You may also be interested in...
Antisoma To Cut Costs After Another Phase III Failure Of A Lead Compound
Antisoma could cut jobs in the U.S. and the U.K. following the failure of its potential secondary acute myeloid leukemia therapy in a Phase III clinical trial.
Antisoma To Cut Costs After Another Phase III Failure Of A Lead Compound
Antisoma could cut jobs in the U.S. and the U.K. following the failure of its potential secondary acute myeloid leukemia therapy in a Phase III clinical trial.
Ahead of ASCO, Exelixis Inks Lucrative Deal With Sanofi For Its PI3 Kinase Inhibitors
Exelixis cashes in on a hot therapeutic drug target, showing that an R&D-focused biotech can succeed in the marketplace.